CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML

Targeted treatment of AML using T cell recruiting antibody constructs

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

Are PARP inhibitors a new standard of care option for MBC patients?

The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

Cancer care in low and middle income countries

Cancer care in Latin America

Surveying cancer patients' mental health and financial problems